Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Sunitinib
100%
Von Hippel-Lindau Disease
100%
Hemangioblastoma
100%
Renal Cell Carcinoma
75%
Von Hippel-Lindau
37%
Fibroblast Growth Factor Receptor 1 (FGFR1)
25%
Laser Scanning Cytometry
25%
Fibroblast Growth Factor 1 (FGF1)
12%
Expression Level
12%
Multiple Organs
12%
Endothelium
12%
Dose Reduction
12%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
12%
Blocking Agent
12%
4-cycle
12%
Two-level
12%
Efficacy Assessment
12%
Modified RECIST
12%
Growth Factor Pathway
12%
Vascular Neoplasms
12%
Day off
12%
Archived Tissue
12%
Biomarker Expression
12%
Medicine and Dentistry
Sunitinib
100%
Von Hippel-Lindau Disease
100%
Hemangioblastoma
100%
Clear Cell Renal Cell Carcinoma
75%
Laser Scanning Cytometry
25%
Fibroblast Growth Factor Receptor
25%
Receptor
12%
Drug Dose Reduction
12%
Vascular Tissue Neoplasm
12%
Biological Marker
12%
Fibroblast Growth Factor
12%
Blocking Agent
12%
Vasculotropin Receptor 2
12%
Efficacy Assessment
12%
Pharmacology, Toxicology and Pharmaceutical Science
Sunitinib
100%
Von Hippel Lindau Disease
100%
Hemangioblastoma
100%
Renal Cell Carcinoma
75%
Fibroblast Growth Factor Receptor
25%
Receptor
12%
Vasculotropin Receptor 2
12%
Biological Marker
12%
Blocking Agent
12%
Vascular Tumor
12%
Fibroblast Growth Factor
12%
Efficacy Assessment
12%
Biochemistry, Genetics and Molecular Biology
Von Hippel-Lindau Disease
100%
Sunitinib
100%
Fibroblast Growth Factor Receptor
50%
Cytometry
50%
Fibroblast Growth Factor
25%
Kinase Insert Domain Receptor
25%
Drug Dose Reduction
25%
Efficacy Assessment
25%